Target intelligence / Profile preview

Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1)

Target
NFATc1
Molecular classification
Transcription factor
01

Overview

Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1) is a DNA-binding transcription factor encoded by the *NFATC1* gene in humans. It plays a central role in inducible gene transcription during immune responses—especially regulating cytokines such as interleukin 2—and controls key aspects of lymphocyte activation, proliferation, differentiation, and apoptosis. The protein functions as part of a complex that translocates from the cytoplasm to the nucleus upon stimulation through the T cell receptor pathway; this process depends on calcium signaling via calcineurin phosphatase activity. Beyond immunity, it also regulates genes involved in cardiac development and osteoclast differentiation/function. It serves as a major molecular target for immunosuppressive drugs like cyclosporin A.

Other names
NFATC1NFAT2Nuclear factor of activated T cells 1Nuclear factor of activated T-cells, cytoplasmic, calcineurin dependent 1
02

Mechanism of action

Immunosuppressive drugs such as cyclosporin A and tacrolimus inhibit calcineurin phosphatase activity, thereby preventing dephosphorylation and nuclear translocation/activation of NFATc1. This blocks transcriptional activation of cytokines critical for T cell activation.

03

Biological functions

Inducible gene transcription during immune responseRegulation of cytokine gene expression (e.g., IL-2, IL-4)Activation and proliferation of T lymphocytesDifferentiation and programmed death (apoptosis) of lymphoid and non-lymphoid cellsOsteoclast differentiation and function (osteoclastogenesis)
04

Disease associations

Cancer (e.g., bladder cancer)Cardiovascular disease (e.g., tricuspid atresia; cardiac valve morphogenesis)Inflammation/immune disorders
05

Safety considerations

Therapeutic targeting can result in broad immunosuppression with increased risk for infection and malignancy due to impaired immune surveillance.Off-target effects may include nephrotoxicity or neurotoxicity when using calcineurin inhibitors like cyclosporin A or tacrolimus.
06

Interacting drugs

Cyclosporin A

2 more in the full profile.

07

Biomarkers

No specific biomarkers are widely used clinically for patient selection or efficacy monitoring based on direct measurement or modulation of NFATc1 activity.

Beyond the preview

Go deeper on Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear factor of activated T-cells, cytoplasmic 1 (NFATc1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call